Thor Medical ASA (FRA:8NN) EBITDA: €-3.49 Mil (TTM As of Dec. 2025)


FRA:8NN Thor Medical ASA FRA:8NN
21 GF Score
Price €0.39
! 2 Warning Signs
View Full Analysis

What is Thor Medical ASA EBITDA?

Thor Medical ASA FRA:8NN +1.71% 21 EBITDA is €-3.49 Mil as of Dec. 2025. GuruFocus rates FRA:8NN with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Thor Medical ASA's EBITDA for the six months ended in Dec. 2025 was €-1.64 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-3.49 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Thor Medical ASA was 77.10% per year. The lowest was -143.10% per year. And the median was -22.50% per year.

Thor Medical ASA's EBITDA per Share for the six months ended in Dec. 2025 was €-0.01. Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Thor Medical ASA was 82.80% per year. The lowest was -100.80% per year. And the median was -14.90% per year.

Thor Medical ASA  (FRA:8NN) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Thor Medical ASA EBITDA Related Terms


Thor Medical ASA EBITDA Historical Data

* Premium members only.

The historical data trend for Thor Medical ASA's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thor Medical ASA EBITDA Chart

Thor Medical ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -42.21 1.07 -0.42 -3.42 -3.44

Thor Medical ASA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.43 -1.10 -2.34 -1.85 -1.64

FRA:8NN vs VRTX, REGN, ALNY: EBITDA Comparison

For the Biotechnology subindustry, Thor Medical ASA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thor Medical ASA EV-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thor Medical ASA's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Thor Medical ASA's EV-to-EBITDA falls into.


FRA:8NN
21GF Score
Thor Medical ASA FRA:8NN
EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Thor Medical ASA's EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Thor Medical ASA's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2025, Thor Medical ASA's EBITDA was €-3.44 Mil.

Thor Medical ASA's EBITDA for the quarter that ended in Dec. 2025 is calculated as

Thor Medical ASA's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Dec. 2025, Thor Medical ASA's EBITDA was €-1.64 Mil.

EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-3.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of €-3.49 Mil mean?
Thor Medical ASA (FRA:8NN) has a EBITDA of €-3.49 Mil as of Dec. 2025. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Thor Medical ASA.
Is Thor Medical ASA's EBITDA too high?
Thor Medical ASA's current EBITDA is €-3.49 Mil. Overall, Thor Medical ASA has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Thor Medical ASA's EBITDA compare to VRTX and REGN?
Thor Medical ASA's EBITDA of €-3.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Biotechnology company?
A good EBITDA depends on the Biotechnology industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Thor Medical ASA. Thor Medical ASA's current EBITDA is €-3.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thor Medical ASA stock overvalued right now?
Thor Medical ASA (FRA:8NN) has a current EBITDA of €-3.49 Mil. The current EBITDA is €-3.49 Mil. Thor Medical ASA's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For Thor Medical ASA (FRA:8NN), the current EBITDA is €-3.49 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Thor Medical ASA Business Description

Other Exchanges TRMED:Norway0R6Y:UK
Address Drammensveien 167, Oslo, NOR, 0277
Thor Medical ASA is a Norway-based biopharmaceutical company. The company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. It uses a proprietary production process that does not involve irradiation or nuclear reactors to produce alpha-emitting materials. These materials are used by radiopharmaceutical companies in the development of cancer therapies.
21GF Score

Get the complete analysis for FRA:8NN

EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.39
Price